PortalPublikationenTreatment with dasatinib for chronic myeloid leukemia follow...

Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity

Standard

Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity. / Harbaum, Lars; Marx, Andreas; Goekkurt, Eray; Schafhausen, Philippe; Atanackovic, Djordje.

in: INT J HEMATOL, Jahrgang 99, Nr. 1, 01.01.2014, S. 91-4.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Harbaum, L, Marx, A, Goekkurt, E, Schafhausen, P & Atanackovic, D 2014, 'Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity', INT J HEMATOL, Jg. 99, Nr. 1, S. 91-4. https://doi.org/10.1007/s12185-013-1474-x

APA

Harbaum, L., Marx, A., Goekkurt, E., Schafhausen, P., & Atanackovic, D. (2014). Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity. INT J HEMATOL, 99(1), 91-4. https://doi.org/10.1007/s12185-013-1474-x

Vancouver

Harbaum L, Marx A, Goekkurt E, Schafhausen P, Atanackovic D. Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity. INT J HEMATOL. 2014 Jan 1;99(1):91-4. https://doi.org/10.1007/s12185-013-1474-x

Bibtex

@article{ca2c4f75c6a045e9b0209dc145adcedf,
title = "Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity",
abstract = "Treatment with the tyrosine kinase inhibitor (TKI) imatinib for chronic myeloid leukemia in chronic phase (CML-CP) of disease may cause severe hepatotoxicity in rare cases. However, it remains unclear (1) how imatinib-induced hepatotoxicity should be treated; and (2) if and how TKI treatment can be resumed after recovery. We report a 32-year-old woman with CML-CP and histology confirmed imatinib-induced liver toxicity after 6 months of treatment. In this case, the early administration of corticosteroid therapy resulted in rapid and complete hepatic recovery, and treatment for CML-CP with the second generation TKI dasatinib was continued safely after recovery. Thus, dasatinib represents an option for maintaining therapeutic response in patients in whom continuation of imatinib is not possible due to its hepatic toxicity.",
author = "Lars Harbaum and Andreas Marx and Eray Goekkurt and Philippe Schafhausen and Djordje Atanackovic",
year = "2014",
month = jan,
day = "1",
doi = "10.1007/s12185-013-1474-x",
language = "English",
volume = "99",
pages = "91--4",
journal = "INT J HEMATOL",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

RIS

TY - JOUR

T1 - Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity

AU - Harbaum, Lars

AU - Marx, Andreas

AU - Goekkurt, Eray

AU - Schafhausen, Philippe

AU - Atanackovic, Djordje

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Treatment with the tyrosine kinase inhibitor (TKI) imatinib for chronic myeloid leukemia in chronic phase (CML-CP) of disease may cause severe hepatotoxicity in rare cases. However, it remains unclear (1) how imatinib-induced hepatotoxicity should be treated; and (2) if and how TKI treatment can be resumed after recovery. We report a 32-year-old woman with CML-CP and histology confirmed imatinib-induced liver toxicity after 6 months of treatment. In this case, the early administration of corticosteroid therapy resulted in rapid and complete hepatic recovery, and treatment for CML-CP with the second generation TKI dasatinib was continued safely after recovery. Thus, dasatinib represents an option for maintaining therapeutic response in patients in whom continuation of imatinib is not possible due to its hepatic toxicity.

AB - Treatment with the tyrosine kinase inhibitor (TKI) imatinib for chronic myeloid leukemia in chronic phase (CML-CP) of disease may cause severe hepatotoxicity in rare cases. However, it remains unclear (1) how imatinib-induced hepatotoxicity should be treated; and (2) if and how TKI treatment can be resumed after recovery. We report a 32-year-old woman with CML-CP and histology confirmed imatinib-induced liver toxicity after 6 months of treatment. In this case, the early administration of corticosteroid therapy resulted in rapid and complete hepatic recovery, and treatment for CML-CP with the second generation TKI dasatinib was continued safely after recovery. Thus, dasatinib represents an option for maintaining therapeutic response in patients in whom continuation of imatinib is not possible due to its hepatic toxicity.

U2 - 10.1007/s12185-013-1474-x

DO - 10.1007/s12185-013-1474-x

M3 - SCORING: Journal article

C2 - 24264834

VL - 99

SP - 91

EP - 94

JO - INT J HEMATOL

JF - INT J HEMATOL

SN - 0925-5710

IS - 1

ER -